近期论文

查看导师新发文章 （温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Mahurkar, S, Moldovan, M, Suppiah, V, Sorosina, M & King, C 2016, 'Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study', The Pharmacogenomics Journal, in press. Eslam, M, Hashem, A, Leung, R, Romero-Gomez, M, Suppiah, V & Santaro, R 2015, 'Interferon-? rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease', Nature Communications, v. 6, no. 6422, pp. 1-10. Rueger, S, Bochud, P, Dufour, J, Mullhaupt, B, Suppiah, V & Negro, F 2015, 'Impact of common risk factors of fibrosis progression in chronic hepatitis C', Gut, v. 64, no. 10, pp. 1605-1615. Flynn, J, Sacks-Davis, R, Higgs, P, Aitken, C, Moneer, S, Suppiah, V, Tracy, L, Ffrench, R, Bowden, S, Drummer, H, George, J, Bharadwaj, M & Hellard, M 2014, 'Detection of HCV-specific IFN-? responses in HCV antibody and HCV RNA negative injecting drug users', Hepatitis Monthly, v. 14, no. 1, article no. e14678. Hopkins, AM, King, CE, Foster, DJR, Suppiah, V, Upton, RN, Spargo, L, Cleland, L, Proudman, SM & Wiese, MD 2014, 'The rheumatoid arthritis susceptibility polymorphism PTPN22 C1858T is not associated with leflunomide response or toxicity', Journal of Clinical Pharmacy and Therapeutics, v. 39, no. 5, pp. 555-560. O'Connor, KS, Ahlenstiel, G, Suppiah, V, Schibeci, S, Ong, A, Leung, R, van der Poorten, D, Douglas, M, Weltman, M, Stewart, G, Liddle, C, George, J & Booth, D 2014, 'IFNL3 mediates interaction between innate immune cells: Implications for hepatitis C virus pathogenesis', Innate Immunity, v. 20, no. 6, pp. 598-605. Wiese, MD, Alotaibi, N, King, CE, Sorich, MJ, Suppiah, V, Cleland, L & Proudman, SM 2014, 'Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis', The Pharmacogenomics Journal, v. 14, pp. 350-355. Wiese, MD, Suppiah, V & King, CE 2014, 'Metabolic and safety issues for multiple sclerosis pharmacotherapy - opportunities for personalised medicine', Expert Opinion on Drug Metabolism and Toxicology, v. 10, no. 8, pp. 1145-1159. Mahurkar, S, Moldovan, M, Suppiah, V & King, CE 2013, 'Identification of Shared Genes and Pathways: A Comparative Study of Multiple Sclerosis Susceptibility, Severity and Response to Interferon Beta Treatment', PLoS One, v. 8, no. 2, article no. e57655. Mahurkar, S, Suppiah, V & King, CE 2013, 'Pharmacogenomics of interferon beta and glatiramer acetate response: A review of the literature', Autoimmunity Reviews, v. 13, pp. 178-186. O'Connor, KS, Parnell, G, Patrick, E, Ahlenstiel, G, Suppiah, V, van der Poorten, D, Read, S, Leung, R, Douglas, M, Yang, J, Stewart, G, Liddle, C, George, J & Booth, D 2013, 'Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent', Genes and Immunity, v. 15, no. 2, pp. 88-94. Sacks-Davis, R, Aitken, C, Higgs, P, Spelman, T, Pedrana, A, Bowden, S, Bharadwaj, M, Nivarthi, U, Suppiah, V, George, J, Grebely, J, Drummer, H & Hellard, M 2013, 'High Rates of Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection in People Who Inject Drugs: A Prospective Cohort Study', PLoS One, v. 8, no. 11, article no. e80216. Suppiah, V, Armstrong, N, O'Connor, KS, Berg, T, Weltman, M, Abate, M, Spengler, U, Bassendine, M, Dore, G, Irving, W, Powell, E, Nattermann, J, Mueller, T, Riordan, S, Stewart, G, George, J, Booth, D & Ahlenstiel, G 2013, 'CCR5-(Delta)32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection', Genes and Immunity, v. 14, no. 5, pp. 286-290. Yip, TSC, King, CE, Tan, N, Dibbens, LM & Suppiah, V 2013, 'SCN1A variations and response to multiple antiepileptic drugs', The Pharmacogenomics Journal, v. 14, no. 4, pp. 385-389. Fischer, J, Bohm, S, Scholz, M, Muller, T, Witt, H, George, J, Sarrazin, C, Susser, S, Schott, E, Suppiah, V, Booth, D, Stewart, G, Van Bommel, F, Brokzinski, A, Fulop, B, Migaud, P & Berg, T 2012, 'Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection', Hepatology, v. 55, no. 6, pp. 1700-1710. Patin, E, Kutalik, Z, Geurgnon, J, Bibert, S, Suppiah, V & Laurent, A and 30 other authors 2012, 'Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection', Gastroenterology, v. 143, no. 5, pp. 1244-1252. Smith, K, Suppiah, V, O'Connor, K, Berg, T, Weltman, M, Abate, M, Spengler, U, Bassendine, M, Mathews, G, Irving, W, Powell, E, Riordan, S, Ahlenstiel, G, Stewart, G, Bahlo, M, George, J & Booth, D 2011, 'Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort', Genome Medicine: medicine in the post-genomic era, v. 3, no. 8. Suppiah, V, Gaudieri, S, Armstrong, NJ, O'Connor, KS & Booth, DR 2011, 'IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European cohort: A cross-sectional study', PLoS Medicine, v. 8, no. 9, article no. e1001092, pp. 1-8. Grebely, J, Petoumenos, K, Hellard, M, Matthews, G, Suppiah, V, Applegate, T, Yeung, B, Marks, P, Rawlinson, W, Lloyd, A, Booth, D, Kaldor, J, George, J & Dore, G 2010, 'Potential role for Interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection', Journal of Gastroenterology and Hepatology, v. 52, no. 4, pp. 1216-1224. Suppiah, V, Moldovan, M, Ahlenstiel, G, Berg, T, Weltman, M, Abate, M, Bassendine, M, Spengler, U, Dore, G, Powell, E, Riordan, S, Sheridan, D, Smedile, A, Fraqomeli, V, Muller, T, Bahlo, M, Stewart, G, Booth, D & George, J 2009, 'IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy', Nature Genetics, v. 41, no. 10, pp. 1100-1104.